Scholarlink

Background <p>FOLFOXIRI plus bevacizumab (BEV) is an option for first-line treatment of metastatic colorectal cancer (mCRC). However, there is no consensus on the optimal treatment strategy when disease progresses. The EFFORT open-label, multicenter, single-arm phase II study investigated whether FOLFIRI plus aflibercept retains activity after progression of FOLFOXIRI plus BEV treatment.</p> Methods <p>The patients with unresectable mCRC who failed first-line FOLFOXIRI plus BEV received FOLFIRI plus aflibercept. The primary endpoint was progression-free survival (PFS) in the full analysis set (FAS). Angiogenic biomarkers were measured before treatment initiation.</p> Results <p>From April 2019 to May 2021, 35 patients were enrolled and 34 were analysed in the FAS population (men, 18; median age, 63&#xa0;years [range: 32–78]). The primary tumor was left-sided in most cases (23/34), 23 patients were <i>RAS</i> mutant, 3 patients had <i>BRAF</i> V600E mutation and 27 patients had liver metastases. The primary end-point was met with a median PFS of 4.3&#xa0;months [80% confidence interval [CI] 3.7–5.1]. Median overall survival was 15.2&#xa0;months [95% CI 8.9–22.7]. Per RECIST, there were 1 complete response, 4 partial responses, 21 stable diseases and 8 disease progressions. Overall response rate was 14.7% [95% CI 5.0–31.1], and disease control rate was 76.5% [95% CI 58.8–89.3]. Responses were more common in patients with high VEGF-C, low VEGF-D and low PlGF levels before treatment.</p> Conclusion <p>FOLFIRI plus aflibercept, administered after failure of FOLFOXIRI plus BEV, is effective and has a manageable safety profile. This regimen may be a useful second-line treatment option for these patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer

  • 期刊论文

  • 发表日期：

    2025年2月1日

查看全文
  • Koji Ando,
  • Hironaga Satake,
  • Mototsugu Shimokawa,
  • Hisateru Yasui,
  • Yuji Negoro,
  • Tatsuya Kinjo,
  • Junya Kizaki,
  • Kenji Baba,
  • Hiroyuki Orita,
  • Keiji Hirata,
  • Sanae Sakamoto,
  • Akitaka Makiyama,
  • Hiroshi Saeki,
  • Akihito Tsuji,
  • Hideo Baba,
  • Eiji Oki

摘要

Background

FOLFOXIRI plus bevacizumab (BEV) is an option for first-line treatment of metastatic colorectal cancer (mCRC). However, there is no consensus on the optimal treatment strategy when disease progresses. The EFFORT open-label, multicenter, single-arm phase II study investigated whether FOLFIRI plus aflibercept retains activity after progression of FOLFOXIRI plus BEV treatment.

Methods

The patients with unresectable mCRC who failed first-line FOLFOXIRI plus BEV received FOLFIRI plus aflibercept. The primary endpoint was progression-free survival (PFS) in the full analysis set (FAS). Angiogenic biomarkers were measured before treatment initiation.

Results

From April 2019 to May 2021, 35 patients were enrolled and 34 were analysed in the FAS population (men, 18; median age, 63 years [range: 32–78]). The primary tumor was left-sided in most cases (23/34), 23 patients were RAS mutant, 3 patients had BRAF V600E mutation and 27 patients had liver metastases. The primary end-point was met with a median PFS of 4.3 months [80% confidence interval [CI] 3.7–5.1]. Median overall survival was 15.2 months [95% CI 8.9–22.7]. Per RECIST, there were 1 complete response, 4 partial responses, 21 stable diseases and 8 disease progressions. Overall response rate was 14.7% [95% CI 5.0–31.1], and disease control rate was 76.5% [95% CI 58.8–89.3]. Responses were more common in patients with high VEGF-C, low VEGF-D and low PlGF levels before treatment.

Conclusion

FOLFIRI plus aflibercept, administered after failure of FOLFOXIRI plus BEV, is effective and has a manageable safety profile. This regimen may be a useful second-line treatment option for these patients.